Core Thesis - Bristol-Myers Squibb Company (BMY) is viewed positively due to its strong dividend history, diversified product portfolio, and potential for long-term growth [1][5]. Financial Performance - As of March 26th, BMY's share price was $59.43, with trailing and forward P/E ratios of 16.61 and 9.20 respectively [1]. - In 2024, BMY reported $48.3 billion in revenue, reflecting a 7% year-over-year increase, with non-GAAP EPS of $1.15 [3]. Dividend and Cash Flow - The company has a 17-year streak of consecutive dividend increases, currently yielding 4.63% with an annual payout of $2.52 per share, supported by strong free cash flow and profitability [2]. Product Portfolio and Growth Potential - Established products like Opdivo and Eliquis provide stable revenues, while growth drugs such as Reblozyl and Breyanzi, along with late-stage candidates like milvexian and admilparant, offer substantial upside potential [3]. - The company plans over ten new product launches by 2030, indicating a strong commitment to innovation [4]. Strategic Partnerships and Market Position - Strategic partnerships, including collaborations with BioNTech and AI-driven initiatives, enhance innovation and strengthen BMY's pipeline [3][4]. - Institutional backing from major firms like Vanguard, BlackRock, and State Street reflects confidence in BMY's strategy and financial stability [4]. Analyst Consensus - Analysts maintain a "Buy" consensus with an average 12-month price target of $57.64, indicating moderate upside potential [5].

Core Insights - The BIOSeedin Winter Innovation Partnering Summit, held on January 11, 2026, in San Francisco, focused on the China Asset Showcase to create a platform for international roadshows and licensing collaborations for Chinese innovative drugs [1] Group 1: Event Overview - The event attracted over 500 industry representatives from more than 10 countries and regions, bringing together multinational companies, leading pharmaceutical firms, biotech companies, and investment institutions across the entire industry chain [2] - Over 300 one-on-one meetings and 18 special roadshows featuring Chinese innovative biotech companies took place, characterized by a dynamic atmosphere of enthusiastic discussions and strong cooperation intentions [2] Group 2: Key Discussions and Presentations - Three cross-border roundtable forums were held, where experienced business development experts and industry leaders discussed oncology, cardio-renal metabolic diseases (CRM), and autoimmune diseases, sharing insights on differentiated therapies for high-incidence cancers and AI-accelerated clinical studies in CRM [3] - The 18 Chinese biotech companies showcased high-quality products in leading areas such as bispecific antibodies, ADCs, and molecular glue, aligning with current industry trends and demonstrating fruitful R&D results in niche areas [3] Group 3: Future Directions - The summit brought together global expertise, activated cross-regional and cross-sector collaboration dynamics, and created a professional bridge for the globalization of innovative drugs from China [4] - BIOSeedin aims to leverage its platform to host high-quality industry events in the future, explore investment opportunities with global partners, and shape the future of biopharmaceutical innovation [4]

Core Viewpoint - Scholar Rock Holding Corporation (SRRK) is a biopharmaceutical company focused on innovative treatments for serious diseases, currently receiving a consensus recommendation of "Buy" from analysts [1] Analyst Recommendations - Sixteen brokerages have provided recommendations for SRRK, including one sell, eleven buy, and four strong buy ratings [1] - Michael Yee from UBS has set a price target of $60 for SRRK, indicating a potential increase of approximately 45.24% from its current price of $41.31 [2][5] - The average 12-month price target among analysts is $48.9, with Barclays raising its target from $45 to $52 while maintaining an "overweight" rating [2][5] - Cantor Fitzgerald reiterated an "overweight" rating on December 11, while Wolfe Research began coverage with an "outperform" rating and a price target of $42 [3] Stock Performance - The stock has experienced fluctuations, with a recent low of $41.19 and a high of $43.06 [4] - Over the past year, SRRK has reached a high of $48.28 and a low of $22.71 [4] - The company's market capitalization is approximately $4.21 billion, with a trading volume of 707,076 shares, indicating active investor interest [4]

Core Insights - Amgen is actively collaborating with the U.S. government to reduce medicine costs for American patients while maintaining its commitment to innovation [1][2] - The company has expanded its direct-to-patient program, AmgenNow, offering significant discounts on certain medications [3] Investment and Manufacturing - Since 2018, Amgen has invested over $40 billion in U.S. manufacturing and research and development, supported by favorable tax policies [4] - In 2025, Amgen announced an additional $2.5 billion in U.S. manufacturing capital investments, including $900 million in Ohio and $1 billion in North Carolina [5] Recognition and Market Position - Amgen has been recognized as one of the "World's Most Innovative Companies" and "America's Best Large Employers" [7] - The company is part of the Dow Jones Industrial Average and the Nasdaq-100 Index, highlighting its significant market presence [7]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Kexing Biopharm Co., Ltd. 科興生物製藥股份有限公司 (A joint stock company incorporated in the People's Republic of China with l ...

“Biopharmaceutical innovation is a global public good. But it is both risky and expensive to carry out,” writes Tomas Philipson. The former chair of America’s Council of Economic Advisers argues for reforms to European drug pricing https://t.co/O3nvcRVuN1 ...

Financial Data and Key Metrics Changes - In Q1 2025, total revenues were $3 billion, driven by higher collaboration revenue from Sanofi and increased U.S. net sales of EYLEA HD compared to the prior year [41] - Diluted net income per share was $8.22, with net income of $928 million [42] - Gross margin on net product sales was 85%, reflecting higher inventory write-offs and a change in product mix [45] - Free cash flow generated in Q1 was $816 million, with cash and marketable securities totaling $17.6 billion and debt of approximately $2.7 billion [46] Business Line Data and Key Metrics Changes - EYLEA U.S. net sales were $736 million, down 39% year-over-year, primarily due to lower physician demand and increased competition [7][29] - EYLEA HD U.S. sales were $307 million, up 54% year-over-year, with physician unit demand growing by 5% [8][30] - DUPIXENT achieved global net sales of $3.7 billion, representing a 20% year-over-year increase, with U.S. sales growing 19% [32] - Libtayo's global net sales grew 8% year-over-year to $285 million, with U.S. sales reaching $193 million, up 21% [38] Market Data and Key Metrics Changes - The branded anti-VEGF category contracted due to increased usage of low-cost off-label repackaged Avastin, which gained approximately 6 percentage points in market share [7][28] - EYLEA and EYLEA HD captured 41% of the anti-VEGF category, maintaining market leadership despite competitive pressures [28] - DUPIXENT continues to lead in new-to-brand prescription share across all approved indications, except for chronic spontaneous urticaria [11][34] Company Strategy and Development Direction - The company aims to capitalize on multiple near-term opportunities across its portfolio, including product enhancements and new medicine launches [27] - Significant investments in R&D are planned, with approximately 45 product candidates in clinical development [12][41] - The company is focused on maintaining leadership in the anti-VEGF category while promoting the adoption of EYLEA HD as the new standard of care [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a mixed performance in Q1 2025, with challenges in the retinal franchise but positive developments in other commercial areas and pipeline advancements [6][7] - The company remains committed to investing heavily in R&D and delivering scientific breakthroughs while maximizing growth opportunities from existing brands [13] - Management expressed confidence in the potential for EYLEA HD and DUPIXENT to continue delivering significant growth [12][34] Other Important Information - The company plans to return capital to shareholders through share repurchases and dividends, with $1.1 billion worth of shares repurchased in Q1 [48] - A new agreement with Fujifilm Diosynth Biotechnologies will invest over $3 billion to nearly double U.S. large-scale manufacturing capacity [46][47] - The company updated its 2025 gross margin guidance to be in the range of 86% to 87% due to higher-than-expected inventory write-offs [49] Q&A Session Summary Question: Can you elaborate on the EYLEA HD CRL for the prefilled syringe? - Management explained that the FDA's questions relate to a third-party component supplier, and they believe the key issue is being addressed. They expect a resolution could be quick, similar to previous CRLs [52][56] Question: How does the company prioritize indications for Factor XI antibodies? - The company prioritizes indications based on the potential to demonstrate benefits in anticoagulation and bleeding risk profiles, with plans to enroll in phase three studies this year [61][63] Question: What are the updated thoughts on foundation funding for EYLEA? - Management discussed the complexities of patient assistance funding and the potential for a matching program to stimulate contributions from others, emphasizing the need for broader support [66][71] Question: Is there acknowledgment of unsatisfactory regulatory performance? - Management took responsibility for the CRLs, attributing them to increased scrutiny by the FDA on contract manufacturers and expressing confidence in their regulatory team's capabilities [87][90]